PD-L1 IHC 22C3 pharmDx Assay

PD-L1 IHC 22C3 pharmDx Assay

OncologyPalliative Care
A badge with ribbon in color black CME Unit: 2 Pts | An analog clock in color black 1 hour | A black calendar with white triangle in center that has a black exclamation point in the middle 17 Nov 2022 

Overview

About this course

PD-L1 IHC 22C3 pharmDx is an assay that detects PD-L1 and is used to identify cancer patients eligible for pembrolizumab therapy. This E-course will give an overview of PD-L1 testing and the assay.

Learning outcomes

PD-L1 testing
  • To provide an overview of PD-1/ PD-L1 checkpoint inhibitors and the importance of PD-L1 testing
  • To discuss the challenges of PD-L1 testing and implications of using LDTs versus IVDs
  • To review the importance of personalised medicine and CDx
PD-L1 IHC 22C3 pharmDx assay
To provide an overview of PD-L1 IHC 22C3 pharmDx assay –
  • Assay overview
  • Scoring guidelines: TPS & CPS
  • Approved indications
  • Platforms: SK006 (Autostainer link) and GE006 (Dako Omnis)
  • Assay validation
Education & training resources
To provide guidance on –
  • Online education & training resources for using and interpreting PD-L1 IHC 22C3 pharmDx assay
  • External quality assurance programs for PD-L1 testing in laboratories

2 CME Points Available

A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.

Sponsored by

Agilent_Logo_RGB.png


Supported by

RCOPOT-Logo.png